Abstract
Imp-I∼III were observed for the first time after a 4-hour thermal degradation study of brivaracetam at 130 °C. These three degradants were prepared and purified through targeted and regiospecific synthesis, and were further characterized by 1D-NMR and 2D-NMR. After differentiation from other isomers, Imp-I was identified as (2S)-2-((3R)-2,5-dioxo-3-propylpyrrolidin-1-yl)butanamide; Imp-II was identified as (2S)-2-((3R,4S)-3-hydroxy-2-oxo-4-propylpyrrolidin-1-yl)butanamide; and Imp-III was identified as (S)-2-(2-oxo-4-propyl-2,5-dihydro-1H-pyrrol-1-yl)butanamide. Besides, in-silico toxicity prediction confirmed a high probability of non-mutagenicity of the three impurities. By preparing and characterizing the degradants, product stability of Brivaracetam under even extreme conditions was better understood, thus further ensuring product quality.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
